

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Westcot Ventures Corp. Announces Listing on the Canadian Securities Exchange

Vancouver, British Columbia – December 27, 2019 – Westcot Ventures Corp. (the “**Company**” or “**Westcot**”) is pleased to announce that, further to its news release on December 23, 2019, the Company's common shares have commenced trading on the Canadian Securities Exchange (the “**CSE**”) under the symbol “WBIO” effective as of market open today.

A listing statement describing the Company and its business, prepared in accordance with the policies of the CSE, is available on the CSE’s website and on SEDAR at www.sedar.com. The information regarding the Company in this press release is qualified in its entirety by reference to the more detailed disclosure included in the listing statement.

About Westcot Ventures Corp.

Westcot is a reporting issuer operating its primary business through its subsidiary WPD Pharmaceuticals Sp. Z.o.o. (“**WPD**”), a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of or licensed to the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.

For further information, please contact:

Westcot Ventures Corp.
Attention: Liam Corcoran,
Canadian Vice President of Legal and Corporate Secretary
Phone: 604-428-7050

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements.

This news release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities.

Cautionary Statements:

Investors are cautioned that, except as disclosed in the Company's CSE listing statement, prepared in accordance with the policies of the CSE, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.